#CD123
Early BPDCN diagnosis matters. ▶️ Watch this on-demand program exploring diagnostic challenges, emerging CD123-targeted therapies, and team-based strategies to guide treatment decisions.

Watch: vist.ly/5qpg9

In partnership with: @nordrare.bsky.social

#BPDCN #Hematology #RareDisease
October 30, 2026 at 3:28 PM
🔬 New in JACI: CD123-targeted CAR-T cells show promise against psoriasis & inflammatory diseases, first proof-of-concept of autologous CAR-T therapy in a humanized model. Made possible by the genO-BRGSF-HIS mouse model.

📖 www.genoway.com/fr/science/p...

🐭 www.genoway.com/fr/product/c...
October 22, 2026 at 11:18 AM
Phase 1 data reported for anti-CD123 CAR T-cell therapy in relapsed or refractory AML, BPDCN
sohoinsider.com/leukemia/pha...
Phase 1 data reported for anti-CD123 CAR T-cell therapy in relapsed or refractory AML, BPDCN
CD123–directed chimeric antigen receptor T-cell therapy was feasible with a favorable safety profile for patients with relapsed or refractory acute myeloid leukemia or blastic plasmacytoid dendritic…
sohoinsider.com
August 21, 2026 at 5:39 PM
Why Is Micro-Cap Aptevo Stock Trading Higher On Wednesday? – Aptevo Therapeutics (NASDAQ:APVO)

Aptevo Therapeutics Inc APVO stock is surging on Wednesday. As per data from Benzinga Pro, the stock is trading higher with a strong volume of 81.8 million compared to the average volume of 275.3k. What…
Why Is Micro-Cap Aptevo Stock Trading Higher On Wednesday? – Aptevo Therapeutics (NASDAQ:APVO)
Aptevo Therapeutics Inc APVO stock is surging on Wednesday. As per data from Benzinga Pro, the stock is trading higher with a strong volume of 81.8 million compared to the average volume of 275.3k. What Happened: Aptevo revealed new clinical data from its ongoing Phase 1b/2 RAINIER trial evaluating mipletamig, its first-in-class CD123 x CD3 bispecific antibody, in combination with standard-of-care venetoclax and azacitidine (ven/aza) for newly diagnosed patients with acute myeloid leukemia (AML) who are unfit…
bdigit24.com
June 18, 2025 at 4:43 PM
でも前ジュクハマの時にCD123枚買ったって人いたな…結局札束バトルなのは変わらんのか…
April 9, 2025 at 12:07 PM
www.nature.com/articles/d41... AbbVie’s pivekimab sunirine has been approved for blastic plasmacytoid dendritic cell neoplasms (BPDCN), a rare and aggressive blood cancer. The 1st-in-class approval expands target space & small-molecule payload arsenal for the antibody–drug conjugate modality.
First CD123-targeted ADC secures FDA approval for rare blood cancer
Discover the world’s best science and medicine | Nature.com
www.nature.com
July 8, 2026 at 10:51 PM
🩸 Hairy cell leukemia!

- Indolent neoplasm of mature B cells—appear w/ cytoplasmic hair-like projections.
- PB cytopenias
- Splenomegaly
- Immunohistophenotyping: CD11c, CD19, CD20 bright, CD22 bright, CD25, CD103, CD123 and CD305 (LAIR)
- BRAF V600E > 95% of cases
#hemesky #pathsky #hemepath
November 27, 2024 at 10:18 AM
At #EHA2026, Prof Martin Wermke (TU Dresden) discusses phase Ia RevSTAR-123 results evaluating AVC-201-01, a first-in-class switchable allogeneic CD123 CAR-T therapy in relapsed/refractory AML. Watch his interview👉https://bit.ly/4xhPbwn
#AML #Haematology #CAR_T
First-in-class switchable allogeneic CAR-T therapy shows promising activity in relapsed or refractory AML - ecancer
Prof Martin Wermke speaks to ecancer about results from the Phase Ia RevSTAR-123 study evaluating AVC-201-01, a switchable allogeneic CD123-targeted CAR-T
bit.ly
August 4, 2026 at 8:05 AM
I’m more worried about the CD123 part than the TALEN part. What happened with anti-CD123 ADCs and biospecifics? https://twitter.com/sxbegle/status/829324509354348544
December 1, 2024 at 10:41 PM
RRIDs were included in this in Blood Advances paper. We value the author's support of reproducibility. #OpenScience #ReproducibleResearch #accelerateopenscience
Vaccine-Educated T cells and a CD123 Bispecific T-Cell Engager for Treatment of Acute Myeloid Leukemia
Read the full paper: Vaccine-Educated T cells and a CD123 Bispecific T-Cell Engager for Treatment of Acute Myeloid Leukemia
doi.org
May 28, 2026 at 7:01 AM
The authors included RRIDs in their paper! Thanks for making your methods matter! #methodsmatter #RRID #RRID
Evaluation of dasatinib and ponatinib for the control of CD123 CAR T-cell functionalities
doi.org
November 23, 2025 at 8:01 AM
The authors included RRIDs in their None paper! We value the author's support of reproducibility. #ReproducibleResearch #accelerateopenscience #accelerateopenscience
CD123 Targeted Epigenetic Nanotherapy for Fusion Oncoprotein MLL-AF9 Rearranged Acute Myeloid Leukemia in Preclinical and Patient Derived Xenograft Models
doi.org
September 17, 2025 at 7:00 AM
RRIDs were included in this None paper. We value the author's support of reproducibility. #STMpublishing #STMpublishing #RRID
The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS
doi.org
August 28, 2025 at 7:00 AM
RRID:AB_2868826 was used by the authors of the Cancer Immunology Research paper "Impact of scFv on functionality and safety of third generation CD123 CAR T cells". RRIDs like this improve reproducibility in scientific research. #reproducibility #STMpublishing
doi.org
February 28, 2025 at 8:02 AM
Innate Pharma Regains Its Rights on CD123 Targeting ANKET ® and Announces Sanofi's Intention to Make a Strategic Investment in the Company

Innate Pharma Regains Its Rights on CD123 Targeting ANKET ® and Announces Sanofi's Intention to Make a Strategic Investment in the Company
Innate Pharma Regains Its Rights on CD123 Targeting ANKET ® and Announces Sanofi's Intention to Make a Strategic Investment in the Company
Innate Pharma Regains Its Rights on CD123 Targeting ANKET ® and Announces Sanofi's Intention to Make a Strategic Investment in the Company
suraj.world
April 23, 2025 at 5:20 AM
Feed: "BIOENGINEER.ORG"
By: Bioengineer on Monday, June 15, 2026
BCG Hsp70–CD123 Immunoconjugate Targets Childhood AML
In a groundbreaking advancement for pediatric oncology, researchers have unveiled a novel immunotherapy strategy that holds promise to revolutionize treatment outcomes for children diagnosed with
bioengineer.org
June 15, 2026 at 9:39 PM
From chemo alone to CD123- and BCL2-directed therapies, BPDCN treatment is evolving. Targeted options and clinical trials are offering new hope in this rare, aggressive disease.

👉 Read more in The Hematologist: https://ow.ly/5q7K50Xa6kb

#MedTwitter #Hematology
October 12, 2025 at 7:00 PM
I am making it my mission to get a proper vorrangsplein built under my radar before Ranty beats me to it.

CD123 can go in the shredder.
April 22, 2025 at 9:36 PM
HCL 的 CD27 是陰性
四個核心評分標記是 CD11c、CD103、CD123、CD25,3–4 分見於約 98% 的 HCL;再加 annexin A1(最具特異性)與 CD200。
CD27 不在其中,而且典型為陰性或弱 —— 把它列入特徵標記就錯了。
CD5、CD10、CD23 也都是陰性。
#血液專科
https://hema-2026.hsiehting.com/q/110-048
August 4, 2026 at 6:45 AM
脾臟相關小 B 細胞腫瘤的鑑別
HCL:CD11c/CD25/CD103/CD123 四陽、annexin A1 陽性、monocytopenia、BRAF V600E。
HCL variant:CD25 與 CD123 陰性、annexin A1 陰性、無 BRAF V600E、單核球正常。
SMZL:NOTCH2、KLF2、del(7q)。
SDRPL:cyclin D3 過度表現。
#血液專科
https://hema-2026.hsiehting.com/q/112-036
August 3, 2026 at 4:36 PM